CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1-Reference-Cited by-同舟云学术

CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1

Published:2024-09-11 Issue:1 Volume:25 Page:
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Zhao Bin¹,Yang Jinye¹,Ran Fengming²,Shi Yuanlong¹,Yang Libo¹,Duan Yuanpeng¹,Shi Zhiyu¹,Li Xin¹,Zhang Jianpeng¹,Li Zhiyao³,Wang Jiansong⁴^ORCID

Affiliation:

1. Department of Urology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China

2. Department of Pathology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China

3. Department of Ultrasound Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China

4. Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

Funder

Yunnan Provincial Department of Science and Technology - Kunming Medical University Joint Special Fund for Applied Basic Research

Scientific Research Fund of Yunnan Provincial Department of Education

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2024.2399363

Reference47 articles.

1. National and subnational trends in cancer burden in China, 2005–20: an analysis of national mortality surveillance data

2. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study

3. Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer

4. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies

5. Prostate-specific antigen-based prostate cancer screening: Past and future